Risk of Streptococcus pneumoniae-associated haemolytic uraemic syndrome in industrialised nations: a systematic review of the literature

Stáhnout PDF English version

Autoři: C. Tung Ho Lok ¹; A. Jien Ting Ser ^2,3; P. Oligbu ⁴; M. Pervaiz ⁵; G. Oligbu ⁶
Působiště autorů: University College London Hospital, London, UK ¹; Oxford University Clinical Academic Graduate School, University of Oxford, Oxford, UK ²; Oxford University Hospitals NHS Foundation Trust, Oxford, UK ³; Department of Family Medicine, University of Benin Teaching Hospital, Nigeria ⁴; Department of Paediatrics, Dumfries and Galloway NHS Hospital, Scotland, UK ⁵; Department of Paediatrics, Dr Gray’s Hospital, NHS Grampian, Scotland, UK ⁶
Vyšlo v časopise: Epidemiol. Mikrobiol. Imunol. 72, 2023, č. 4, s. 213-220
Kategorie: Původní práce

Souhrn

Background and Aim: Haemolytic uraemic syndrome (HUS) is a triad of haemolytic anaemia, thrombocytopaenia, and acute kidney injury. It is a leading cause of acute kidney injury in children and has a high rate of long-term sequelae. Streptococcus pneumoniae–associated HUS (SpHUS) is a rare complication from pneumococcal disease. This article aims to systematically review SpHUS following the global introduction of pneumococcal conjugate vaccines (PCVs).

Material and Methods: A comprehensive literature search was conducted in MEDLINE, EMBASE, and the Cochrane library from 1st January 2000 to 13th April 2022.

Results: Thirteen studies were included in this review, involving a total of 7,177 children with HUS, of which 336 cases were associated with Streptococcus pneumoniae. SpHUS accounted for 4.8% of all HUS cases, in which most patients were younger than 24 months old. Nine studies (80.4%, 281) were during the country’s PCV era, whereas 4 studies (19.6%, 66) were before the introduction of PCV into the national vaccination programme. Pneumonia was the commonest clinical presentation (77.3%; 75/97), followed by septicaemia (33.0%; 32/97), and meningitis (29.9%; 29/97). Most cases presenting with pneumonia were complicated by empyema or pleural effusion (54.4%, n=49/90). Only 5 studies reported the isolated serotypes, with the most prevalent serotype being 19A (44.4%, n=20/45), followed by serotype 3 (17.8%, n = 8/45) and 7F (6.7%, n = 3/45). Of those reporting fatality, there were 12 deaths with a fatality rate of 9.8% (n = 12/122).

Conclusion: SpHUS is rare, but commonly presents in children younger than 2 years old. There remains a high risk of long-term complications and relatively high mortality rate even in the era of conjugate vaccines.

Zdroje

Gerber A, Karch H, Allerberger F, et al. Clinical course and the role of Shiga toxin-producing Escherichia coli infection in the hemolytic-uremic syndrome in pediatric patients, 1997–2000, in Germany and Austria: A prospective study. J Infect Dis., 2002;186(4):493–500.
Lawrence J, Gwee A, Quinlan C. Pneumococcal haemolytic uraemic syndrome in the postvaccine era. Arch Dis Child, 2018;103(10):957–961.
Salvadori M. Update on hemolytic uremic syndrome: Diagnostic and therapeutic recommendations. World J Nephrol., 2013;2(3):56.
Bitzan M, Lapeyraque AL. Pediatric kidney disease: Second edition. In: Pediatric Kidney Disease: Second Edition. 2017. p. 653– 731.
Copelovitch L, Kaplan BS. Streptococcus pneumoniae-associated hemolytic uremic syndrome. Pediatr Nephrol., 2008;23(11):1951–1956.
Agarwal HS, Latifi SQ. Streptococcus pneumoniae-associated hemolytic uremic syndrome in the era of pneumococcal vaccine. Pathogens, 2021;10(6).
Novak R, Martin C, Orsini E. Hemolytic-uremic syndrome and T-cryptantigen exposure by neuraminidase-producing pneumococci: an emerging problem? Pediatr Pathol, 1983;(1):409–413.
Ramasethu J, Luban NLC. T activation. Br J Haematol, 2001; 112(2):259–263.
Gilbert RD, Nagra A, Haq MR. Does dysregulated complement activation contribute to haemolytic uraemic syndrome secondary to streptococcus pneumoniae? Med Hypotheses, 2013;81(3):400–403.
Meinel C, Spartà G, Dahse HM, et al. Streptococcus pneumoniae from Patients with Hemolytic Uremic Syndrome Binds Human Plasminogen via the Surface Protein PspC and Uses Plasmin to Damage Human Endothelial Cells. J Infect Dis, 2018;217(3):358– 370.
Scobell RR, Kaplan BS, Copelovitch L. New insights into the pathogenesis of Streptococcus pneumoniae–associated hemolytic uremic syndrome. Pediatr Nephrol., 2020;35(9):1585–1591.
Bender JM, Ampofo K, Byington CL, et al. Epidemiology of streptococcus pneumoniae-induced hemolytic uremic syndrome in Utah children. Pediatr Infect Dis J, 2010;29(8):712–716.
Lee CS, Chen MJ, Chiou YH, et al. Invasive pneumococcal pneumonia is the major cause of paediatric haemolytic-uraemic syndrome in Taiwan. Nephrology, 2012;17(1):48–52.
Holle J, Habbig S, Gratopp A, et al. Complement activation in children with Streptococcus pneumoniae associated hemolytic uremic syndrome. Pediatr Nephrol., 2021;36(5):1311–1315.
Gómez Delgado I, Corvillo F, Nozal P, et al. Complement Genetic Variants and FH Desialylation in S. pneumoniae-Haemolytic Uraemic Syndrome. Front Immunol., 2021;12.
Vilardouro AS, Cachão J, Rodrigues M, et al. Hemolytic-uremic syndrome: 24 years’ experience of a pediatric nephrology unit. Brazilian J Nephrol., 2022;51–59.
Constantinescu AR, Bitzan M, Weiss LS, et al. Non-enteropathic hemolytic uremic syndrome: Causes and short-term course. Am J Kidney Dis., 2004;43(6):976–982.
Proulx F, Sockett P. Prospective surveillance of Canadian children with the haemolytic uraemic syndrome. Pediatr Nephrol., 2005;20(6):786–790.
Cochran JB, Panzarino VM, Maes LY, et al. Pneumococcus-induced T-antigen activation in hemolytic uremic syndrome and anemia. Pediatr Nephrol., 2004;19(3):317–321.
Waters AM, Kerecuk L, Luk D, et al. Hemolytic Uremic Syndrome Associated with Invasive Pneumococcal Disease: The United Kingdom Experience. J Pediatr., 2007;151(2):140–144.
Copelovitch L, Kaplan BS. Streptococcus pneumoniae Associated hemolytic uremic syndrome: Classification and the emergence of serotype 19A. Pediatrics, 2010;125(1).
Prestidge C, Wong W. Ten years of pneumococcal-associated haemolytic uraemic syndrome in New Zealand children. J Paediatr Child Health, 2009;45(12):731–735.
Veesenmeyer AF, Edmonson MB. Trends in US hospital stays for Streptococcus pneumoniae-associated hemolytic uremic syndrome. Pediatr Infect Dis J., 2013;32(7):731–735.
Lynn RM, O’Brien SJ, Taylor CM, et al. Childhood hemolytic uremic syndrome, United Kingdom and Ireland. Emerg Infect Dis, 2005;11(4):590–596.
Nyman A, Pitchumani S, Jaffe A, et al. Pneumococcal empyema and haemolytic uraemic syndrome in children: experience from a UK tertiary respiratory centre. Arch Dis Child, 2009;94(8):645– 646.
Byington C, Spencer L, Johnson T, et al. An Epidemiologic Investigation of a Sustained High Rate of Pediatric Parapneumonic Empyema: Risk Factors and Microbiological Associations. Clin Pediatr (Phila), 2002;34(4):434–440.
van der Linden M, Weiß S, Falkenhorst G, et al. Four years of universal pneumococcal conjugate infant vaccination in Germany: Impact on incidence of invasive pneumococcal disease and serotype distribution in children. Vaccine, 2012;30(40):5880–5885.
Whitney C, Farley M, Hadler J, et al. Decline in Invasive Pneumococcal Disease after the Introduction of Protein–Polysaccharide Conjugate Vaccine. N Engl J Med, 2013;348(18):1737–1746.
Andrews NJ, Waight PA, Burbidge P, et al. Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: A postlicensure indirect cohort study. Lancet Infect Dis, 2014;14(9):839–846.
Oligbu G, Hsia Y, Folgori L, et al. Pneumococcal conjugate vaccine failure in children: A systematic review of the literature. Vaccine, 2016;34(50):6126–6132.
Snape MD, Klinger CL, Daniels ED, et al. Immunogenicity and reactogenicity of a 13-valent-pneumococcal conjugate vaccine administered at 2, 4, and 12 months of age: A double-blind randomized active-controlled trial. Pediatr Infect Dis J, 2010;29(12):80–90.
Balloch A, Licciardi P V., Russell FM, et al. Infants aged 12 months can mount adequate serotype-specific IgG responses to pneumococcal polysaccharide vaccine. J Allergy Clin Immunol, 2010;126(2):395–397.
Hsiao HJ, Wu CT, Huang JL, et al. Clinical features and outcomes of invasive pneumococcal disease in a pediatric intensive care unit. BMC Pediatr, 2015;15(1):1–6.
Backhaus E, Berg S, Andersson R, et al. Epidemiology of invasive pneumococcal infections: Manifestations, incidence and case fatality rate correlated to age, gender and risk factors. BMC Infect Dis, 2016;16(1):1–12.
Cabrera G, Fortenberry J, Warshaw B, et al. Hemolytic uremic syndrome associated with invasive Streptococcus pneumoniae infection. Pediatrics, 1998;101:699–703.
Kielstein JT, Beutel G, Fleig S, et al. Best supportive care and therapeutic plasma exchange with or without eculizumab in Shiga-toxin-producing E. coli O104:H4 induced haemolyticuraemic syndrome: An analysis of the German STEC-HUS registry. Nephrol Dial Transplant, 2012;27(10):3807–3815.
Spinale JM, Ruebner RL, Kaplan BS, et al. Update on Streptococcus pneumoniae associated hemolytic uremic syndrome. Curr Opin Pediatr, 2013;25(2):203–208.
Loirat C, Saland J, Bitzan M. Management of hemolytic uremic syndrome. Press Medicale, 2012;41(3 PART 2):e115–135.
Brandt J, Wong C, Mihm S, et al. Invasive Pneumococcal Disease and Hemolytic Uremic Syndrome. Pediatrics, 2002;110(2):371– 376.
Zens KD, Baroutsou V, Fehr JS, et al. Pneumococcal Vaccination Coverage and Uptake Among Adults in Switzerland: A Nationwide Cross-Sectional Study of Vaccination Records. Front Public Heal, 2022;9:1–10.
Hill H, Elam-Evans L, Yankey D, et al. National, State, and Selected Local Area Vaccination Coverage Among Children Aged 19–35 Months – United States, 2014. MMWR Morb Mortal Wkly Rep, 2015;64(33):889–896.